JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2016, Vol. 54 ›› Issue (1): 52-57.doi: 10.6040/j.issn.1671-7554.0.2015.1042
Previous Articles Next Articles
ZHANG Xuequn1, GAO Wei2, PAN Pan3, GAO Junyi4
CLC Number:
[1] Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012[J]. CA Cancer J Clin, 2012, 62(4):220-241. [2] Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2):69-90. [3] Ward E, Hao Y, Xu J. Cancer statistics[J]. CAJ Cancer Clin, 2009, 59(4):225-249. [4] Siegel R, Naishadham D, Jemal A. Cancer statistics[J]. CAJ Clin, 2013, 63(1):11-30. [5] Ward SG, Finan P. Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents[J]. Curr Opin Pharmacol, 2003, 3(4):426-434. [6] Pene F, Claessens YE, Muller O, et a1. Role of the Dhosphatidylinositol 3-kinase/Akt and mT0R/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma[J]. Oncogene, 2002, 2l(43):6587-6597. [7] Rychahou PG, Murillo CA, Evers BM. Targeted RNA interference of PI3K pathway components sensitizes colon cancer cells to TNF-related apoptosis-inducing ligand(TRAIL)[J]. Surgery, 2005, 138(2):391-397. [8] Shao J, Washington MK, Saxena R, et al. Heterozygous disruption of the PTEN promotes intestinal neoplasia in APC min/+mouse roles of osteopontin[J]. Carcinogenesis, 2007, 28(12):2476-2483. [9] Ellis L, Ku SY, Ramakrishnan S, et al. Combinatorial antitumor effect of HDAC and the PI3K -Akt -mTOR pathway inhibition in a Pten deficient model of prostate cancer[J]. Oncotarget, 2013, 27(5):122-135. [10] Hales EC, Taub JW, Matherly LH, et al. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis:Targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia[J]. Cell Signal, 2014, 26(1):149-161. [11] Yentrapalli R, Azimzadeh O, Sriharshan A, et al. The PI3K/Akt/mTOR pathway is implicated in the premature senescence of primary human endothelial cells exposed to chronic radiation[J]. PLoS One, 2013, 11(1):181-226. [12] Slattery ML, Herrick JS, Lundgreen A, et al. Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk:mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1[J]. Carcinogenesis, 2010, 31(9):1604-1611. [13] 彭秋平, 梁后杰, 边志衡, 等. mTOR信号通路调控HK-Ⅱ表达对结肠癌细胞增殖的影响[J]. 现代肿瘤医学, 2007, 15(6):760-762. [14] 李宝秀, 李春燕, 刘国龙, 等. 雷帕霉素靶蛋白在ⅢB期结肠癌中的异常表达及其意义[J]. 解放军医学杂志, 2010, 35(8):961-965. [15] Johnson SM, Gulhati P, Rampy BA, et al. Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer[J]. J Am Coll Surg, 2010, 210(5):767-776. [16] Cheung M, Testa JR. Diverse mechanisms of AKT pathway activation in human malignancy[J]. Curr Cancer Drug Targets, 2013, 13(3):234-244. [17] Viglietto G, Motti ML, Bruni P, et al. Cytoplasmic relocalization and inhibition of the cyclin- dependent kinase inhibitor p27(Kip1)by PKB/Akt-mediated phosphorylation in breast cancer[J]. Nat Med, 2002, 8(10):1136-1144. [18] Gao N, Zhang Z, Jiang BH, et al. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K /AKT /mTOR /p70S5K1 signaling in human ovarian cancer cells[J]. Am J Physiol Cell Physiol, 2004, 287(2):281-291. [19] Hua KQ, Feng WW, Cao Q, et al. Estrogen and progestin regulate metastasis through the PI3K /AKT pathway in human ovarian cancer[J]. Int J of Oncology, 2008, 33(5):959-967. [20] Morsaki T, Uchiyam A, Yuzuki D, et al. Interleukin 4 regulates G1 cell progression in colorectal carcinoma cell[J]. Cancer Res, 2004, 54(4):1113-1118. [21] 陈小贺, 孟文格, 孟繁杰, 等. CyclinD1、CDK4和Rb在大肠癌中的表达及意义[J]. 肿瘤防治研究, 2006, 33(6):428-430. |
[1] | LIU Huiling, WANG Xingwen, FENG Shaobin, FENG Hong, HAN Junqing. Association between high expression of scavenger receptor class B type I and the prognosis of colon cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(10): 84-89. |
[2] | WANG Yao, CHEN Yan-hong, CHEN Hong. Correlation between sensibility, and side effects of 5-FU and DPYD gene polymorphisms in periphrel blood of patients with colon cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(S1): 18-21. |
[3] | QIU Huihui1, YE Liping1, WEN Youfeng2, LI Dan1, SONG Jia1. Effects of IL-6 on the expressions of bcl-2,cyclinD1 and VEGF in ovarian cancer cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(6): 17-21. |
[4] | MENG Xian-peng1, LIU Jie2, SU Ya3, BING Xue4, GAO Wei2. Inhibitive effect of SU11274 on human colon cancer (LOVO cell line)transplanted in nude mice [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(2): 20-24. |
[5] | SUN Xiu-mei1, GAO Feng2, LIU Zi-feng3. Inhibition of Salinomycin on the characteristics of colon cancer stem cell [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(9): 40-44. |
[6] | DAI Jun1, LIU Pei-shu1, MA Dao-xin2, CHANG Xin-zhong1, FENG Jin-bo1, YIN Ge-ping3. Expressions of cyclinD1 in ovarian cancer transplanted into nude mice [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(6): 57-60. |
[7] |
ZHANG Rui-yu, L Zhi-mei, LIU Yi, ZHANG Peng-ju, WAN Qiang, WANG Rong.
The mRNA-stabilizing factor Human-Antigen R regulates renal cyclinD1 post-transcriptional expression in human mesangial cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(2): 47-52. |
[8] | LI Wan-quan1, ZHU Xiao-lin2, YU Cheng-gong2. Effects of sodium butyrate on cell proliferation and expression of ICAM-1 in the HT-29 colon cancer cell line [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(11): 70-. |
|